Comparison of F-18-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL (R) approaches: Validation against histopathology
Vincent Dore, Santiago Bullich, Christopher C Rowe, Pierrick Bourgeat, Salamata Konate, Osama Sabri, Andrew W Stephens, Henryk Barthel, Jurgen Fripp, Colin L Masters, Ludger Dinkelborg, Olivier Salvado, Victor L Villemagne, Susan De Santi
ALZHEIMERS & DEMENTIA | ELSEVIER SCIENCE INC | Published : 2019
INTRODUCTION: 18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. METHODS: Data from eighty-eight subjects (52 male subjects, aged 79.8 ± 10.6 years) who underwent antemortem 18F-florbetaben positron emission tomography scan and magnetic resonance imaging less than a year before neuropathological assessment at autopsy were evaluated. Image analysis was performed using the standard Centiloid (CL) statistical parametric mapping approach and CapAIBL®. Imaging results were compared against autopsy dat..View full abstract
Related Projects (2)
Awarded by NHMRC
This study was supported in part by Life Molecular Imaging and NHMRC Project Grants 1044361, 1011689, and 1071430, and by the Alzheimer's Australia Dementia Research Foncation - Victoria Project Grant.